Wall Street’s September 29 watchlist: Earnings, space bets and a market without a side
Tuesday opens with Wall Street still refusing to choose a broad direction. Major indices remain close to flat, while money keeps rotating into narrow, headline-driven themes.
Traders favour space, defence, artificial-intelligence infrastructure, biotech deals and company-specific earnings. Broad buying remains harder to find, and that changes the day’s playbook.
A sharp headline can create an opening gap, but volume and guidance decide whether that move survives lunch. In this tape, selective conviction matters more than market-wide optimism.
CarMax clears expectations, but faces a tougher second act
CarMax reported fiscal second-quarter earnings of $1.16 a share, against consensus near $0.73. Revenue reached roughly $7.88 billion, well above forecasts around $7.09 billion.
The result gives KMX the morning’s clearest earnings surprise. Yet traders will look beyond the headline beat before assigning the shares a durable rerating.
CarMax offers a live reading on the American consumer, used-car pricing and borrowing costs. Investors will scrutinise unit volumes, retail margins and wholesale performance.
Auto-finance losses also deserve attention, especially after years of higher rates and stretched household budgets. Stronger credit trends could support the bullish case.
A large opening gap often pulls in momentum buyers, but it also invites swift profit-taking. KMX needs to hold its opening range to keep the story intact.
Management’s outlook matters most. A better forecast for demand, financing and margins would suggest the quarter was more than an isolated beat.
Carnival becomes a consumer-spending test
Carnival reports with estimates varying noticeably between data providers. One preview expects $1.42 a share on $8.54 billion in revenue.
Another places expectations nearer $1.35 a share and $8.39 billion in sales. That gap matters because the market trades against positioning, not a theoretical consensus.
Booking trends may carry more weight than the reported profit figure. Investors will watch ticket prices, onboard spending, fuel costs and debt reduction.
Strong bookings would support the view that consumers still prioritise travel experiences. Softer commentary could unsettle that view, even with an earnings beat.
CCL has become a useful barometer for discretionary demand after the pandemic travel rebound. The shares may also move with any change in pricing discipline.
For traders, Carnival is not merely an earnings event. It is a real-time judgement on consumer confidence and leisure spending.
Oracle’s data-centre delay puts execution under the microscope
Oracle has slipped after reports of a force-majeure notice linked to a New Mexico data-centre project. The company reportedly sought delayed payments if construction slips.
The development raises questions about timing, financing and customer commitments. Still, a single delayed project does not automatically break Oracle’s wider AI infrastructure story.
ORCL remains a closely watched beneficiary of rising cloud and data-centre spending. Its backlog has helped investors look past the enormous cost of expansion.
The market now needs to judge the scale of the disruption. A quick recovery would suggest investors view the issue as manageable.
Heavy selling on expanding volume would send a different message. That would imply concerns about the speed and cost of Oracle’s AI buildout.
Space and defence retain momentum, with expensive expectations
Rocket Lab, Voyager Technologies and Navitas Semiconductor remain lodged in a favoured corner of the market. Space, defence and power technology have attracted persistent speculative interest.
Rocket Lab benefits from launch activity and rising defence relevance. Reports of an $8 billion acquisition, though, require confirmation through a filing or company statement.
In this sector, the gap between a rumour and a signed transaction can move a share price violently. Traders should not confuse ambitious talk with a completed deal.
Voyager’s reported relationship with Anduril offers a strategically appealing angle. Yet partnerships need contract values and customer commitments before they become revenue forecasts.
Navitas has drawn attention through a reported US Army award involving high-voltage silicon-carbide technology. The award could improve credibility, while near-term sales may remain modest.
These themes can run hard, but they carry familiar hazards. Dilution, funding needs, delayed programmes and valuation compression can quickly puncture momentum.
Summit gains a powerful biotech vote of confidence
Summit Therapeutics has attracted buyers after AstraZeneca reportedly committed $2 billion in equity investment. The companies also plan combination studies involving ivonescimab.
The deal provides a meaningful financing catalyst and validates Summit’s programme. It does not, however, guarantee clinical success, approval or commercial sales.
Biotech valuations still rest on probabilities, not promises. SMMT therefore belongs among speculative catalyst trades, rather than lower-risk growth holdings.
The next test is institutional demand after the initial reaction. Sustained buying would matter more than a short burst of celebratory volume.
Upgrades and overbought charts need more proof
Meta’s possible multiple expansion depends on future AI monetisation, rather than a single identifiable event. That makes the debate longer-term and less suited to chasing sudden gaps.
Analyst targets on Robinhood and FuelCell Energy also require context. The analyst, assumptions, publication date and current price all shape their value.
Netflix remains a sentiment-recovery watch after bullish commentary. An upgrade alone rarely justifies buying a sharp opening move.
Stitch Fix faces a Market Perform downgrade from William Blair. That is more neutral than aggressively bearish, but it offers little fresh support.
Target cuts for Boot Barn, Western Union and Rollins may flag relative weakness. They do not automatically create clean short positions.
High RSI readings in Horizon Global, Hamilton Beach Brands and Kandi Technologies carry the same warning. Overbought shares can remain overbought while trends strengthen.
- KMX: Watch used-car volumes, finance losses and the first-hour trading range.
- CCL: Focus on bookings, pricing, onboard spending and debt commentary.
- ORCL: Measure the data-centre concern through volume and any project detail.
- SMMT: Treat the AstraZeneca investment as validation, not clinical certainty.
- Space names: Demand filings, contract values and evidence of funded revenue.
Tuesday’s market rewards separation between information and interpretation. CarMax has delivered measurable numbers, while Carnival offers a consumer-demand verdict.
Oracle presents an execution concern, and biotech offers a high-stakes financing catalyst. The strongest trades may be the ones that hold their gains after attention moves elsewhere.
Related coverage on Volity
- What Is a P/E Ratio and How to Use It
- Fundamental Analysis in Stock Trading: A Working Definition
- Growth Investing vs Value Investing: Which Style Fits You?
- Fractional Shares Explained: How to Start Investing With $50
- How to Start Stock Trading: A 2026 Beginner Guide
- Dividend Investing for Beginners: How to Start
